Want to see AU:CU6 full AI Analyst Report?
Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$2.50
â–Ľ(-20.13% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily held back by weak financial performance—widening losses, persistent negative free cash flow, and shrinking equity—despite the benefit of having no debt. Technicals are mixed with only short-term strength versus longer-term trend weakness, and valuation support is limited because earnings are negative and no dividend yield is available.
Positive Factors
Debt-free balance sheet
Zero reported debt lowers financial fixed-cost burden and reduces solvency pressure during the clinical development cycle. For a cash-burning biotech, having no interest obligations preserves flexibility to fund trials or negotiate partnerships without immediate refinancing stress, supporting multi-quarter durability.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow means ongoing reliance on external funding or dilution to sustain operations. Increased outflows in the latest year accelerate runway consumption, pressuring management to secure financing or partnerships that could dilute shareholders or alter strategic priorities over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt lowers financial fixed-cost burden and reduces solvency pressure during the clinical development cycle. For a cash-burning biotech, having no interest obligations preserves flexibility to fund trials or negotiate partnerships without immediate refinancing stress, supporting multi-quarter durability.
Read all positive factors
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$899.13M
Dividend YieldN/A
Average Volume (3M)3.27M
Price to Earnings (P/E)―
Beta (1Y)2.57
Revenue GrowthN/A
EPS Growth-70.72%
CountryAU
Employees88
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.28
Shares Outstanding373,081,240
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$8.41Price Target Upside168.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)AU$1.40M
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranost...
How the Company Makes Money
null...
Clarity Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.77M | 9.46M | 11.51M | 9.80M | 6.46M | 3.20M |
| Gross Profit | 4.62M | 9.46M | 11.51M | 9.70M | 6.41M | 3.18M |
| EBITDA | -101.51M | -68.91M | -44.65M | -34.20M | -30.15M | -13.38M |
| Net Income | -96.25M | -64.30M | -42.32M | -24.60M | -23.75M | -10.22M |
Balance Sheet | ||||||
| Total Assets | 255.67M | 101.17M | 154.63M | 76.90M | 99.82M | 22.61M |
| Cash, Cash Equivalents and Short-Term Investments | 226.25M | 84.12M | 136.51M | 65.01M | 92.34M | 18.94M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 22.86M | 10.94M | 8.33M | 7.72M | 7.59M | 2.34M |
| Stockholders Equity | 232.81M | 90.23M | 146.30M | 69.18M | 92.24M | 20.28M |
Cash Flow | ||||||
| Free Cash Flow | -72.59M | -54.95M | -43.74M | -27.55M | -13.53M | -7.74M |
| Operating Cash Flow | -72.26M | -54.77M | -43.24M | -27.50M | -13.31M | -7.68M |
| Investing Cash Flow | -47.91M | 51.99M | -55.31M | 3.15M | -26.71M | -60.31K |
| Financing Cash Flow | 193.45M | 2.21M | 115.21M | 231.58K | 86.93M | 10.91M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Neutral
3.13
Price Trends
2.45
Negative
2.88
Negative
3.35
Negative
Market Momentum
>-0.01
Negative
54.28
Neutral
65.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CU6, the sentiment is Neutral. The current price of 3.13 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.45, and below the 200-day MA of 3.35, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 65.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CU6.
Clarity Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$5.53B | -506.85 | -1.72% | ― | 59.13% | -121.52% | |
55 Neutral | AU$67.34M | -1.24 | -93.08% | ― | 116.02% | 75.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$309.38M | -95.45 | -15.96% | ― | 364.97% | 74.50% | |
46 Neutral | AU$899.13M | -9.11 | -59.59% | ― | ― | -70.72% | |
42 Neutral | AU$429.39M | -40.48 | -47.44% | ― | ― | -15.48% | |
40 Underperform | AU$75.16M | -0.89 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:CU6
Clarity Pharmaceuticals Ltd.
2.41
-0.65
-21.24%
AU:IMM
Immutep Ltd
0.05
-0.19
-79.18%
AU:SPL
Starpharma Holdings Limited
0.74
0.64
642.42%
AU:TLX
Telix Pharmaceuticals
16.27
-7.18
-30.62%
AU:RAC
Race Oncology Ltd.
2.19
1.03
88.79%
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-13.64%
Clarity Pharmaceuticals Ltd. Corporate Events
Vanguard Cuts Stake Below Substantial Holder Threshold in Clarity Pharmaceuticals
Jul 6, 2026
Vanguard Group has notified Clarity Pharmaceuticals that it has ceased to be a substantial holder in the company as of 1 July 2026, reducing its voting power to 4.751%. The change in Vanguard’s relevant interest, set out in regulatory filing...
Clarity Pharmaceuticals Issues New Shares Following Option Exercise
Jul 1, 2026
Clarity Pharmaceuticals has issued 110,000 fully paid ordinary shares following the exercise of options, expanding its share capital without providing a disclosure document under the relevant provisions of the Corporations Act, while confirming co...
Clarity Pharmaceuticals Seeks ASX Quotation for Additional 110,000 Shares
Jul 1, 2026
Clarity Pharmaceuticals Ltd has applied for quotation on the ASX of 110,000 additional ordinary fully paid shares under its CU6 ticker, with the new securities issued on July 1, 2026. The issue, arising from the exercise or conversion of existing ...
Clarity’s SAR-bisPSMA data set to showcase prostate cancer advances at EANM 2026
Jun 29, 2026
Clarity Pharmaceuticals will present new data on its copper-based SAR-bisPSMA imaging and therapy agents at the European Association of Nuclear Medicine Congress 2026 in Vienna, underscoring the growing clinical profile of its prostate cancer port...
Clarity Pharmaceuticals marks 100-staff milestone as it builds radiopharmaceutical capabilities
Jun 25, 2026
Clarity Pharmaceuticals has reached a 100-employee milestone, reflecting rapid headcount growth of about 45% in the current financial year and a strong focus on talent in the U.S. and Australia. The company emphasises advanced qualifications, ongo...
Regal Partners exits substantial holding in Clarity Pharmaceuticals
Jun 25, 2026
Regal Partners Funds Management Pty Ltd and related entities have ceased to be substantial holders in Clarity Pharmaceuticals Ltd., after a series of on-market share sales between 17 and 23 June 2026. The disposals, which cumulatively reduced thei...
State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Jun 22, 2026
State Street Corporation and several of its asset management subsidiaries have lodged a notice that they have ceased to be a substantial holder in Clarity Pharmaceuticals Ltd as of 18 June 2026, under Section 671B of the Corporations Act. The chan...
Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme
May 27, 2026
Clarity Pharmaceuticals has notified the market of the issuance of 19,485 unquoted options under its employee incentive scheme, with various expiry dates and exercise prices. The move modestly expands the company’s unquoted equity base and r...
Clarity Pharmaceuticals Director Sells Shares to Cover Tax from Option Exercise
Apr 22, 2026
Clarity Pharmaceuticals has disclosed that Managing Director Michelle Parker sold 360,896 shares on 20 April 2026 to fund a tax liability stemming from the exercise of share options. The company stressed that the transaction is a one-off, with Par...
Clarity Expands U.S. Manufacturing Network for Prostate Cancer Imaging Agent
Apr 13, 2026
Clarity Pharmaceuticals has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for Cu-64 SAR-bisPSMA, expanding its U.S. manufacturing footprint through facilities in Rochester, Minnesota, and a planned large-scale site in Spring...
Citigroup Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Apr 10, 2026
Citigroup Global Markets Australia Pty Limited and related Citi group entities have notified Clarity Pharmaceuticals that they have ceased to be a substantial shareholder as of 8 April 2026, ending their previous substantial holding status in the ...
Clarity Pharmaceuticals Director Colin Biggin Steps Down but Retains Significant Equity Stake
Apr 9, 2026
Clarity Pharmaceuticals has announced that director Colin David Biggin has ceased to be a director of the company as of 8 April 2026. A final director’s interest notice filed with the ASX details that Biggin retains holdings in the company, ...
Clarity Pharmaceuticals Reshapes Board as It Moves Toward Commercial Launch
Apr 8, 2026
Clarity Pharmaceuticals has announced a change to its board, with Executive Director Dr Colin Biggin stepping down from the board while continuing in his operational role as Chief Operating Officer. The move is part of a broader corporate governan...
Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme
Apr 7, 2026
Clarity Pharmaceuticals has notified the market of the issue of 59,857 unquoted options under an employee incentive scheme, recorded as two tranches of CU6AAM options with varying expiry dates and exercise prices. The new options, issued on 23 and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.